ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 52 filers reported holding ENANTA PHARMACEUTICALS INC in Q3 2013. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $36,000 | -5.3% | 720 | -2.7% | 0.00% | 0.0% |
| Q1 2020 | $38,000 | -17.4% | 740 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $46,000 | +4.5% | 740 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $44,000 | 0.0% | 740 | +42.3% | 0.00% | +100.0% |
| Q2 2019 | $44,000 | -12.0% | 520 | 0.0% | 0.00% | -50.0% |
| Q1 2019 | $50,000 | -61.2% | 520 | -71.4% | 0.00% | -60.0% |
| Q4 2018 | $129,000 | -25.4% | 1,820 | -9.9% | 0.01% | 0.0% |
| Q3 2018 | $173,000 | +408.8% | 2,020 | +198.4% | 0.01% | +400.0% |
| Q4 2014 | $34,000 | +25.9% | 677 | 0.0% | 0.00% | 0.0% |
| Q3 2014 | $27,000 | -6.9% | 677 | 0.0% | 0.00% | 0.0% |
| Q2 2014 | $29,000 | -61.8% | 677 | -64.5% | 0.00% | -66.7% |
| Q1 2014 | $76,000 | +13.4% | 1,907 | -22.4% | 0.00% | 0.0% |
| Q4 2013 | $67,000 | +19.6% | 2,457 | 0.0% | 0.00% | +50.0% |
| Q3 2013 | $56,000 | – | 2,457 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 862,848 | $42,556,000 | 14.73% |
| Fairmount Funds Management LLC | 171,147 | $8,441,000 | 3.56% |
| ARMISTICE CAPITAL, LLC | 1,648,000 | $81,279,000 | 1.87% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,995,000 | $98,393,000 | 0.49% |
| Jackson Creek Investment Advisors LLC | 21,409 | $1,056,000 | 0.37% |
| Hennion & Walsh Asset Management, Inc. | 113,940 | $5,620,000 | 0.34% |
| Virtus ETF Advisers LLC | 14,721 | $726,000 | 0.31% |
| Granahan Investment Management | 193,416 | $9,539,000 | 0.20% |
| Yorktown Management & Research Co Inc | 4,500 | $222,000 | 0.18% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 242,257 | $11,948,000 | 0.09% |